NCT01024322

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 1,189 (actual)
• Sponsor: Cxlusa · Industry
• Sex: All
• Age: 8 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication

Conditions

• Keratoconus
• Ectasia
• Degeneration

Interventions

Type	Name	Description
DRUG	Ciprofloxicine or Vigamox or other.	Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
DRUG	Nonsteroidal (Acular, Voltaren Xibrom, etc)	Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
DRUG	Steroid (FML, Pred Forte, Flarex, etc.)	Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.

Timeline

• Start date: 2009-10-01
• Primary completion: 2017-02-03
• Completion: 2017-02-03
• First posted: 2009-12-02
• Last updated: 2018-10-11

Locations

3 sites across 1 country: United States